Cost–Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes in Sweden

Diabetes Therapy

Volumn 5, Issue 2, 2014, Pages 591-607

  Kiadaliri, Aliasghar A ^a,b   Gerdtham, Ulf G ^a,c   Eliasson, Bjorn ^d   Carlsson, Katarina Steen ^a,e  

^a LUND UNIVERSITY   (Sweden)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c LUND UNIVERSITY   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e SWEDISH INSTITUTE FOR HEALTH ECONOMICS   (Sweden)

Author keywords

Cost utility analysis; DPP 4 inhibitors; GLP 1 agonists; Insulin; Sweden; Type 2 diabetes

Indexed keywords

CHOLESTEROL; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE RECEPTOR AGONIST; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISOPHANE INSULIN; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SAXAGLIPTIN; SITAGLIPTIN; TRIACYLGLYCEROL; VILDAGLIPTIN;

ADULT; ARTICLE; BODY MASS; COST UTILITY ANALYSIS; DIASTOLIC BLOOD PRESSURE; DRUG COST; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HYPOGLYCEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SIMULATION; SYSTOLIC BLOOD PRESSURE;

EID: 84919617689     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-014-0080-0     Document Type: Article

References (66)

1. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103(2):137–49.
2. Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, Shaw J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(3):293–301.
3. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–12.
4. Perkovic V, Heerspink HL, Chalmers J, Woodward M, Jun M, Li Q, et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int. 2013;83(3):517–23.
5. Zoungas S, Chalmers J, Ninomiya T, Li Q, Cooper ME, Colagiuri S, et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia. 2012;55(3):636–43.
6. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72.
7. American Diabetes Association. Executive summary: standards of medical care in diabetes—2011. Diabetes Care. 2011;34(Suppl 1):S4–10.
8. National Board of Health and Welfare. National guidelines for diabetes care. 2nd edn. Vasteras, Sweden, 2010. http://www.socialstyrelsen.se/nationalguidelines/nationalguidelinesfordiabetescare. Accessed Feb 20, 2014.
9. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. American Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statement—executive summary. Endocr Pract. 2013;19(3):536–57.
10. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55(6):1577–96.
11. Russell S. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction. Int J Clin Pharm. 2013;35(2):159–72.
12. Cederholm J, Nilsson P. A review of risk factors and cardiovascular disease in diabetes care—2011. Eur J Cardiovasc Med. 2011;3(1):21–5.
13. The Swedish National Diabetes Register. https://www.ndr.nu. Accessed June 2, 2014.
14. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA. 2010;303(14):1410–8.
15. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007;147(6):386–99.
16. Deacon CF, Mannucci E, Ahren B. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. Diabetes Obes Metab. 2012;14(8):762–7.
17. Nauck M, Frid A, Hermansen K, Thomsen AB, During M, Shah N, et al. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Obes Metab. 2013;15(3):204–12.
18. Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771. doi:10.1136/bmj.d7771.
19. McIntosh B, Cameron C, Singh SR, Yu C, Ahuja T, Welton NJ, et al. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. Open Med. 2011;5(1):e35–48.
20. Steen Carlsson K, Persson U. Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin. J Med Econ 2014;1–23. doi:10.3111/13696998.2014.933110.
21. Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Zbrozek AS, Dong F, et al. Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care. 1997;20(5):725–34.
22. Brown JB, Russell A, Chan W, Pedula K, Aickin M. The global diabetes model: user friendly version 3.0. Diabetes Res Clin Pract. 2000;50(Suppl 3):S15–46.
23. Bagust A, Hopkinson PK, Maier W, Currie CJ. An economic model of the long-term health care burden of Type II diabetes. Diabetologia. 2001;44(12):2140–55.
24. Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia. 2004;47(10):1747–59.
25. Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia. 2013;56(9):1925–33.
26. Ahmad Kiadaliri A, Gerdtham UG, Nilsson P, Eliasson B, Gudbjornsdottir S, Carlsson KS. Towards renewed health economic simulation of type 2 diabetes: risk equations for first and second cardiovascular events from Swedish register data. PLoS One. 2013;8(5):e62650. doi:10.1371/journal.pone.0062650.
27. Ekstrom N, Miftaraj M, Svensson AM, Andersson Sundell K, Cederholm J, Zethelius B, et al. Glucose-lowering treatment and clinical results in 163,121 patients with type 2 diabetes: an observational study from the Swedish national diabetes register. Diabetes Obes Metab. 2012;14(8):717–26.
28. Canadian Agency for Drugs and Technologies in Health, Second- and Third-Line Pharmacotherapy for Type 2 Diabetes: Update. Vol. Ottawa: The Agency; 2013. (CADTH optimal use report; vol. 3, no. 1a). 2013, Ottawa (ON).
29. Pratley R, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract. 2011;65(4):397–407.
30. Aschner P, Chan J, Owens DR, Picard S, Wang E, Dain MP, et al. Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Lancet. 2012;379(9833):2262–9.
31. Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther. 2007;29(11):2333–48.
32. Kilo C, Mezitis N, Jain R, Mersey J, McGill J, Raskin P. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications. 2003;17(6):307–13.
33. Milicevic Z, Hancu N, Car N, Ivanyi T, Schwarzenhofer M, Jermendy G. Effect of two starting insulin regimens in patients with type II diabetes not controlled on a combination of oral antihyperglycemic medications. Exp Clin Endocrinol Diabetes. 2009;117(5):223–9.
34. Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, Yan P, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376(9739):431–9.
35. Monnier L, Colette C. Addition of rapid-acting insulin to basal insulin therapy in type 2 diabetes: indications and modalities. Diabetes Metab. 2006;32(1):7–13.
36. Pontiroli AE, Miele L, Morabito A. Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. Diabetes Obes Metab. 2011;13(11):1008–19.
37. Pontiroli AE, Miele L, Morabito A. Metabolic control and risk of hypoglycaemia during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. Diabetes Obes Metab. 2012;14(5):433–46.
38. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group. Am J Med 1991;90(4):450–9.
39. Grzeszczak W, Czupryniak L, Kolasa K, Sciborski C, Lomon ID, McEwan P. The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland. Diabetes Technol Ther. 2012;14(1):65–73.
40. Erhardt W, Bergenheim K, Duprat-Lomon I, McEwan P. Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis. Clin Drug Investig. 2012;32(3):189–202.
41. Woehl A, Evans M, Tetlow AP, McEwan P. Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes in the United Kingdom. Cardiovasc Diabetol. 2008;7:24. doi:10.1186/1475-2840-7-24.
42. Smith-Palmer J, Fajardo-Montanana C, Pollock RF, Ericsson A, Valentine WJ. Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. J Med Econ. 2012;15(5):977–86.
43. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, Vahatalo M, Virtamo H, Nikkila K, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 2006;49(3):442–51.
44. Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ. 2009;180(4):385–97.
45. Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Plank J, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007;2:CD005613. doi:10.1002/14651858.CD005613.pub3.
46. U.K. prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995;44(11):1249–58.
47. Chaudhry ZW, Gannon MC, Nuttall FQ. Stability of body weight in type 2 diabetes. Diabetes Care. 2006;29(3):493–7.
48. NICE. Technology appraisal guidance 288—Dapagliflozin in combination therapy for treating type 2 diabetes. http://guidance.nice.org.uk/TA288/PublicInfo/pdf/English. Accessed April 4, 2014.
49. NICE. Canagliflozin for the Treatment of Type 2 Diabetes Mellitus. http://www.nice.org.uk/guidance/index.jsp?action=download&o=66677. Accessed April 4, 2014.
50. Intensive blood–glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):837–53.
51. Ringborg A, Martinell M, Stalhammar J, Yin DD, Lindgren P. Resource use and costs of type 2 diabetes in Sweden—estimates from population-based register data. Int J Clin Pract. 2008;62(5):708–16.
52. Dental and Pharmaceutical Benefits Agency in Sweden. http://www.tlv.se. Accessed April 11, 2014.
53. Owens D, Barnett A, Pickup J, Kerr D, Bushby P, Hicks D, et al. Blood glucose self-monitoring in type 1 and type 2 diabetes: reaching a multidisciplinary consensus. Diabetes Prim Care. 2004;6(1):8–16.
54. Ekman M, Consumption and production by age in Sweden. Basic facts and health economic implications. In: Ekman M, editor. Studies in health economics: modelling and data analysis of costs and survival. Stockholm; 2002.
55. Kiadaliri AA, Gerdtham U, Eliasson B, Gudbjörnsdottir S, Svensson AM, Carlsson KS. Health utilities of type 2 diabetes-related complications: a cross-sectional study in Sweden. Int J Environ Res Public Health. 2014;11(5):4939–52.
56. Ericsson A, Pollock RF, Hunt B, Valentine WJ. Evaluation of the cost–utility of insulin degludec vs insulin glargine in Sweden. J Med Econ. 2013;16(12):1442–52.
57. Evans M, Khunti K, Mamdani M, Galbo-Jorgensen CB, Gundgaard J, Bogelund M, et al. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health Qual Life Outcomes. 2013;11:90. doi:10.1186/1477-7525-11-90.
58. Carlsson P, Anell A, Eliasson M. Hälsoekonomi får allt större roll för sjukvårdens prioriteringar. Läkartidningen. 2006;103(46):3617–23.
59. ®) in type 2 diabetes in Sweden. Prim Care Diabetes. 2012;6(2):127–36.
60. Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ. 2005;14(3):217–30.
61. Davies MJ, Chubb BD, Smith IC, Valentine WJ. Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus. Diabet Med. 2012;29(3):313–20.
62. Lee WC, Samyshkin Y, Langer J, Palmer JL. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis. J Med Econ. 2012;15(Suppl 2):28–37.
63. Mezquita Raya P, Perez A, Ramirez de Arellano A, Briones T, Hunt B, Valentine WJ. Incretin therapy for type 2 diabetes in Spain: a cost-effectiveness analysis of liraglutide versus sitagliptin. Diabetes Ther. 2013;4(2):417–30.
64. AhmadKiadaliri A, Clarke PM, Gerdtham UG, Nilsson P, Eliasson B, Gudbjornsdottir S, et al. Predicting changes in cardiovascular risk factors in Type 2 diabetes in the post-UKPDS era: longitudinal analysis of the Swedish National Diabetes Register. J Diabetes Res. 2013;2013:241347. doi:10.1155/2013/241347.
65. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20(Suppl 1):S5–26.
66. Li WX, Gou JF, Tian JH, Yan X, Yang L. Glucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Curr Ther Res Clin Exp. 2010;71(4):211–38.